Motif Bio PLC (LON:MTFB) (NASDAQ:MTFB) has appointed long-standing board member Bruce Williams as its interim chairman to replace Richard C.E. Morgan who is stepping down with immediate effect to focus on other business commitments.
The AIM-listed group said Morgan has agreed to remain available to the company in the coming months on an as needed basis to ensure a smooth transition.
The company pointed out that Williams has significant operational experience in the biopharmaceutical industry and has held senior leadership positions at both large pharmaceutical firms and start-up biotechs.
It said he served as senior vice president, global business management at Enzon Pharmaceuticals, where he led the company's commercial functions, prior to that, he was senior vice president, sales & marketing at Genta Incorporated.
Graham Lumsden, Motif Bio’s chief executive officer commented: "We are delighted that Bruce has agreed to step into the interim Chairman role. He is a strong leader who has held senior executive positions, particularly in strategic product planning and commercialisation, at a number of biopharmaceutical companies.”
The CEO added: “I look forward to continuing to work with him as Motif Bio seeks to advance iclaprim towards approval. We have submitted a meeting request and package to the FDA and expect to work collaboratively with the Agency over the coming weeks."